Payment overview · 2025
General Payments
$9,946.53
111 reported records · 22 companies
Healthcare provider profile · identity verified
Khalid B Mohammed, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · RIVERVIEW, FL · NPI 1740701093
Verified facts
What the public records show
CMS Open Payments records show Khalid B Mohammed, DO received $9,946.53 in general payments during 2025 across 111 reported records.
Abbott Laboratories accounted for 35.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $3,488.48 | 35.1% | 19 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,801.12 | 18.1% | 32 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $1,502.16 | 15.1% | 4 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $576.37 | 5.8% | 7 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $390.22 | 3.9% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $315.89 | 3.2% | 5 | 2025 |
| Contego Medical, Inc | Unresolved — no canonical attribution shown | $287.97 | 2.9% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $267.77 | 2.7% | 5 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $262.08 | 2.6% | 4 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $247.85 | 2.5% | 3 | 2025 |
| Procyrion, Inc. | Unresolved — no canonical attribution shown | $137.84 | 1.4% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $119.33 | 1.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $86.09 | 0.9% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $76.45 | 0.8% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $69.72 | 0.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.13 | 0.6% | 4 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $58.56 | 0.6% | 4 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $53.81 | 0.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.97 | 0.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.39 | 0.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.17 | 0.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.16 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,554.38 | 94 |
| Travel and Lodging | $4,392.15 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $1,751.69 | 7 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $1,431.08 | 4 | 2025 |
Source payment records
|
|||||
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $1,269.62 | 3 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $390.22 | 3 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $262.08 | 4 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $247.85 | 3 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $232.54 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $231.31 | 5 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $191.73 | 3 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $179.52 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $179.52 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $166.78 | 1 | 2025 |
Source payment records
|
|||||
| AORTIX SYSTEM Normalized: aortix system |
Device | Procyrion, Inc. | $137.84 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER TALISMAN Normalized: amplatzer talisman |
Device | Abbott Laboratories | $129.00 | 1 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $120.41 | 1 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM Septal Occluder Normalized: gore cardioform septal occluder |
Device | W. L. Gore & Associates, Inc. | $119.33 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $113.81 | 1 | 2025 |
Source payment records
|
|||||
| Laser CVX300 Normalized: laser cvx300 |
Device | Philips North America LLC | $94.40 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $86.09 | 1 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $85.81 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $76.45 | 4 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $69.82 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.13 | 4 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $58.56 | 4 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $56.58 | 4 | 2025 |
Source payment records
|
|||||
| Denali Vena Cava Filter Normalized: denali vena cava filter |
Device | Bard Peripheral Vascular, Inc. | $53.81 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.97 | 2 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $43.84 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| IGT Devices Systems Undivided Normalized: igt devices systems undivided |
Device | Philips North America LLC | $29.76 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $27.92 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $19.39 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| INTHRILL THROMBECTOMY CATHETER Normalized: inthrill thrombectomy catheter |
Device | Stryker Corporation | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $12.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 14 | suppressed |
| Furosemide | Furosemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $9,946.53 · 111 records | Abbott Laboratories | ABRE, ALPHAVAC, AMPLATZER TALISMAN, ANGIOVAC, AORTIX SYSTEM, ARTIX MT, ASSURITY, AURORA EV-ICD MRI SURESCAN, Assure WCD, CARDIOMEMS, CLOT MANAGEMENT, CT THROMBECTOMY SYSTEM KIT, Denali Vena Cava Filter, ELUVIA, ESPRIT, FARXIGA, FLOWTRIEVER CATHETER, S, GORE CARDIOFORM Septal Occluder, HAWKONE, IGT Devices Systems Undivided, INSPIRE, INTHRILL THROMBECTOMY CATHETER, Indigo System, JARDIANCE, Labosys, Laser CVX300, LifeVest, MICRA, OPTIS, PERCLOSE PROSTYLE, PROTEGE RX, REPATHA, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VYNDAQEL, Varithena Administration Pack, WAINUA, WATCHMAN FLX, Wegovy, XIENCE SKYPOINT | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error